The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Samarium-153     samarium

Synonyms: AC1L3G8Q, 153Sm, Samarium, isotope of mass 153
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of samarium


High impact information on samarium


Chemical compound and disease context of samarium


Biological context of samarium


Anatomical context of samarium

  • The onset of drug absorption occurred 4 hours after administration when radioactive samarium-153 was in the distal small bowel, and peak plasma drug level occurred 6 hours after administration, which corresponded with the arrival of samarium-153 in the terminal ileum and ileal/cecal junction [17].

Associations of samarium with other chemical compounds


Gene context of samarium

  • IFN-gamma, IL-4 and beta-ACT were detected with europium (Eu), terbium (Tb) and samarium (Sm) labelled probes, respectively, using time-resolved fluorometry [21].
  • The subsequent immunoassay, including the separation of free and bound HCA I and II, requires only one incubation step, after which an enhancement solution dissociates Sm3+ and Eu3+ ions from the labeled HCA I and II, respectively, into a solution where they form highly fluorescent chelates [22].

Analytical, diagnostic and therapeutic context of samarium


  1. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. Anderson, P.M., Wiseman, G.A., Dispenzieri, A., Arndt, C.A., Hartmann, L.C., Smithson, W.A., Mullan, B.P., Bruland, O.S. J. Clin. Oncol. (2002) [Pubmed]
  2. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. Serafini, A.N., Houston, S.J., Resche, I., Quick, D.P., Grund, F.M., Ell, P.J., Bertrand, A., Ahmann, F.R., Orihuela, E., Reid, R.H., Lerski, R.A., Collier, B.D., McKillop, J.H., Purnell, G.L., Pecking, A.P., Thomas, F.D., Harrison, K.A. J. Clin. Oncol. (1998) [Pubmed]
  3. Samarium-153 chelate localization in malignant melanoma. Turner, J.H., Martindale, A.A., de Witt, G.C., Webb, J., Sorby, P., Boyd, R.E. European journal of nuclear medicine. (1987) [Pubmed]
  4. Pharmacokinetics and biodistribution of samarium-153-labelled OC125 antibody coupled to CITCDTPA in a xenograft model of ovarian cancer. Kraeber-Bodéré, F., Mishra, A., Thédrez, P., Faivre-Chauvet, A., Bardiès, M., Imai, S., Le Boterff, J., Chatal, J.F. European journal of nuclear medicine. (1996) [Pubmed]
  5. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Tian, J.H., Zhang, J.M., Hou, Q.T., Oyang, Q.H., Wang, J.M., Luan, Z.S., Chuan, L., He, Y.J. European journal of nuclear medicine. (1999) [Pubmed]
  6. Dual-label time-resolved fluoroimmunoassay for simultaneous detection of myoglobin and carbonic anhydrase III in serum. Vuori, J., Rasi, S., Takala, T., Väänänen, K. Clin. Chem. (1991) [Pubmed]
  7. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. Singh, A., Holmes, R.A., Farhangi, M., Volkert, W.A., Williams, A., Stringham, L.M., Ketring, A.R. J. Nucl. Med. (1989) [Pubmed]
  8. Radiation dose calculations in persons receiving injection of samarium-153 EDTMP. Logan, K.W., Volkert, W.A., Holmes, R.A. J. Nucl. Med. (1987) [Pubmed]
  9. Targeted and systemic radiotherapy in the treatment of bone metastasis. Lin, A., Ray, M.E. Cancer Metastasis Rev. (2006) [Pubmed]
  10. Teletherapy and radiopharmaceutical therapy of painful bone metastases. Silberstein, E.B. Seminars in nuclear medicine. (2005) [Pubmed]
  11. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate. Turner, J.H., Claringbold, P.G. Eur. J. Cancer (1991) [Pubmed]
  12. Clinical outcome after one year following samarium-153 particulate hydroxyapatite radiation synovectomy. Clunie, G., Lui, D., Cullum, I., Ell, P.J., Edwards, J.C. Scand. J. Rheumatol. (1996) [Pubmed]
  13. Samarium-153 ethylenediamine tetramethylene phosphonate therapy for bone pain palliation in skeletal metastases. Tripathi, M., Singhal, T., Chandrasekhar, N., Kumar, P., Bal, C., Jhulka, P.K., Bandopadhyaya, G., Malhotra, A. Indian journal of cancer. (2006) [Pubmed]
  14. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Finlay, I.G., Mason, M.D., Shelley, M. The lancet oncology. (2005) [Pubmed]
  15. Samarium for osteoblastic bone metastases and osteosarcoma. Anderson, P. Expert opinion on pharmacotherapy. (2006) [Pubmed]
  16. Efficacy and safety of repeated samarium-153 lexidronam treatment in a patient with prostate cancer and metastatic bone pain. Menda, Y., Bushnell, D.L., Williams, R.D., Miller, S., Thomas, M.O. Clinical nuclear medicine. (2000) [Pubmed]
  17. Explaining variable absorption of a hypolipidemic agent (CGP 43371) in healthy subjects by gamma scintigraphy and pharmacokinetics. Sun, J.X., Walter, B., Sandefer, E.P., Page, R.C., Digenis, G.A., Ryo, U.Y., Cipriano, A., Maniara, W.M., Powell, M.L., Chan, K. Journal of clinical pharmacology. (1996) [Pubmed]
  18. Dual-label time-resolved immunofluorometric assay for simultaneous determination of pregnancy-associated plasma protein A and free beta-subunit of human chorionic gonadotrophin. Qin, Q., Christiansen, M., Lövgren, T., Nørgaard-Pedersen, B., Pettersson, K. J. Immunol. Methods (1997) [Pubmed]
  19. Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation. Hogan, W.J., Lacy, M.Q., Wiseman, G.A., Fealey, R.D., Dispenzieri, A., Gertz, M.A. Bone Marrow Transplant. (2001) [Pubmed]
  20. Dual-isotope imaging of neutron-activated erbium-171 and samarium-153 and the in vivo evaluation of a dual-labeled bilayer tablet by gamma scintigraphy. Digenis, G.A., Sandefer, E.P., Beihn, R.M., Parr, A.F. Pharm. Res. (1991) [Pubmed]
  21. Simultaneous detection of IFN-gamma and IL-4 mRNAs using RT-PCR and time-resolved fluorometry. Halminen, M., Sjöroos, M., Mäkelä, M.J., Waris, M., Terho, E., Lövgren, T., Ilonen, J. Cytokine (1999) [Pubmed]
  22. A competitive dual-label time-resolved immunofluorometric assay for simultaneous detection of carbonic anhydrase I and II in cerebrospinal fluid. Parkkila, A.K., Parkkila, S., Serlo, W., Reunanen, M., Vierjoki, T., Rajaniemi, H. Clin. Chim. Acta (1994) [Pubmed]
  23. Labeling of monoclonal antibodies with samarium-153 for combined radioimmunoscintigraphy and radioimmunotherapy. Boniface, G.R., Izard, M.E., Walker, K.Z., McKay, D.R., Sorby, P.J., Turner, J.H., Morris, J.G. J. Nucl. Med. (1989) [Pubmed]
  24. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis. Serafini, A.N. The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR). (2001) [Pubmed]
WikiGenes - Universities